In fact, van Eyben et al. [140] systematically analyzed PRLT with 177Lu-PSMA-617 and 177Lu-PSMA-I&T against third-line treatment of PC with abiraterone, enzalutamide, and cabazitaxel. The gene discussed is FOLH1; the disease is pachyonychia congenita.